The Cost Cure: Ashish Jha's Case for Price Caps, Competition, and Biosurveillance

Send us Fan Mail

Episode Summary
Anthony DiGiorgio and Anish Koka speak with Dr. Ashish Jha, co-founder and CEO of BioRadar, senior fellow at Harvard Belfer Center, and former White House COVID-19 response coordinator, about the future of American healthcare policy. The conversation moves from hospital pricing and insurance design to Medicaid, HSA-based models, and the political realities that shape what reform is actually possible. They also pivot into a second major topic: biothreat detection. Jha explains why he thinks biosurveillance, not just response, will be essential in an era of AI-assisted biological engineering.

Timestamps
00:00 - Intro, guest credentials, and the Boston Globe cost cure series
00:33 - Why Jha wrote a 10-part reform series instead of one op-ed
01:54 - Evidence-based ideas that should annoy someone on every side
03:42 - Why state-level health policy matters, not just Washington
04:20 - American healthcare’s core pricing problem
05:58 - Competition, monopolies, and when price regulation enters the picture
06:57 - Scope of practice, insurance design, and administrative burden
08:40 - Indiana’s Medicaid-based hospital pricing experiment
09:47 - Why provider price caps are controversial
11:42 - Site-neutral payments and the hospital lobbying problem
13:30 - Why temporary regulation can bridge a monopoly-heavy market
16:22 - Why payer competition matters before price caps can reach consumers
17:44 - Can temporary government policies ever really be reversed?
20:11 - Tackling the demand-side subsidies that fuel consolidation
22:39 - FTC enforcement and the slow pace of market change
23:53 - Why policy experts should give leaders workable alternatives
26:27 - Hospitals are not villains, but incentives matter
27:32 - Site-neutral payment and physician-owned hospitals as starting points
28:57 - Cash payments, deductibles, and value-based insurance design
29:49 - The outline of a possible deal among hospitals, insurers, and policymakers
33:34 - Medicaid work requirements and what the evidence says
35:36 - Why eligibility should be easier for people who qualify
38:02 - Medicaid as a value statement about universal coverage
40:19 - Program integrity, fraud, and long-term sustainability
43:43 - Why Jha changed his mind on pay-for-performance and EHRs
45:14 - His critique of quality metrics and the value of empirical humility
46:14 - Why HSAs are attractive but imperfect
47:23 - Living under an HSA and why behavior changes
49:47 - Why Medicare for All is politically and operationally hard
50:41 - Uwe Reinhardt, Denmark, and why systems depend on politics and people
53:18 - Why sick people often make irrational cost decisions
57:02 - Smarter copays, true emergencies, and the limits of consumerism
58:24 - Why disagreement should stay respectful and not personal
60:20 - Pivot to bioterrorism and biological weapons
61:07 - Why BioRadar was created and what problem it is solving
63:18 - AI, state actors, and the shrinking barrier to bioweapons
64:18 - Why the risk of an engineered pathogen in the next five years worries Jha
65:31 - Jha’s view that COVID was more likely a lab leak than a natural origin
66:30 - Guardrails around gain-of-function research and Fauci criticism
68:46 - The difference between a dangerous outbreak and a stealth pandemic
71:38 - How biosurveillance can avoid overreaction while still catching real threats
73:13 - Why better surveillance could have changed the COVID response
75:16 - Wrap-up, bipartisanship, and the value of trade-offs

Co-Host Handles
@anish_koka and @DrDiGiorgio
Show Handle
@DRsLoungePod

Subscribe Links
Spotify: https://open.spotify.com/show/44vw8eirsKKnjgNIrdDvrR
Apple Podcasts: https://podcasts.apple.com/us/podcast/the-doctors-lounge/id1832097658
YouTube: https://www.youtube.com/@TheDoctorsLoungePod

🔗 Connect with the Hosts:

• Dr. Anthony DiGiorgio on X

• Dr. Anish Koka on X

• Dr. Dan Choi on X

• Dr. Sanat Dixit on X